Author:
Gassman Jennifer J.,Greene Tom,Wright Jackson T.,Agodoa Lawrence,Bakris George,Beck Gerald J.,Douglas Janice,Jamerson Ken,Lewis Julia,Kutner Michael,Randall Otelio S.,Wang Shin-Ru
Abstract
ABSTRACT. The African American Study of Kidney Disease and Hypertension (AASK) is a multicenter randomized clinical trial designed to test the effectiveness of three anti-hypertensive drug regimens and two levels of BP control on the progression of hypertensive kidney disease. Participants include African-American men and women aged 18 to 70 yr who have hypertensive kidney disease and GFR between 20 and 65 ml/min per 1.73 m2. The three anti-hypertensive drug regimens include an angiotensin converting enzyme inhibitor (ramipril), a dihydropyridine calcium channel blocker (amlodipine) or a beta-blocker (metoprolol) as initial therapy. The BP control levels are a lower goal (mean arterial pressure, ≤92 mmHg) and a usual goal (mean arterial pressure, 102 to 107 mmHg inclusive). The primary outcome is rate of change in renal function as measured by GFR, assessed by 125 I-iothalamate clearance. The main secondary patient outcome is a composite including the following events: (1) reduction in GFR by 50%, (2) end-stage renal disease, or (3) death. E-mail: jgassman@bio.ri.ccf.org
Publisher
American Society of Nephrology (ASN)
Subject
Nephrology,General Medicine
Reference56 articles.
1. US Renal Data System: USRDS 2001 Annual Data Report, Atlas of End Stage Renal Disesase in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, 2001
2. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
3. Hypertension as a Causative Diagnosis of Patients Entering End-Stage Renal Disease Programs in the United States From 1980 to 1986
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献